Navigation Links
Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
Date:6/11/2009

patients who were given Caldolor reported a significant reduction in post-surgical pain intensity within the first 24 hours while also significantly reducing their morphine use. Clinical trials including critically ill and non-critically ill patients with fever showed a significant reduction in temperature as compared with those who received a placebo. No serious adverse events were directly attributed to Caldolor in any of these clinical studies.

"We are delighted to obtain FDA approval for the first and only intravenous treatment for pain and fever in the U.S. market," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Cumberland is dedicated to providing innovative products that improve quality of care for patients and address unmet medical needs. We believe Caldolor represents a significant addition to our product portfolio and a substantial market opportunity."

Caldolor is the third drug in Cumberland's portfolio and the second for which Cumberland has completed development and secured FDA approval. The company will promote Caldolor in the United States through its expanded hospital sales force and will use alliances with marketing partners for sales outside of the United States. Caldolor is expected to be available in the U.S. later this year.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patient
'/>"/>

SOURCE Cumberland Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
2. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
5. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
6. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
7. Jubilant to Work With Endo Pharmaceuticals on Drug Development
8. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
9. ADVENTRX Pharmaceuticals Announces Financing
10. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... continuous operation up to 1500 bar. The sanitary design gauge of the NS2006L ... contamination. , The Pony™ NS2006L homogenizer is an ideal solution for the processing ...
(Date:7/29/2015)... US-Australian drug discovery company, Novogen Limited (ASX: NRT; NASDAQ: ... progressing its ground-breaking technology platforms to Phase 1 clinical ... Company delivers the best value for shareholders. ... the Company currently had an extensive program of activities ... academic partnerships and initiatives, and he was working with ...
(Date:7/29/2015)... 2015  AsureQuality and Ubiquitome have agreed to ... in food and primary production sectors. The collaboration ... device, the Freedom4. AsureQuality provides quality ... supermarket shelf for producers, processors and Competent Authorities ... disease control and pest management and surveillance programmes. ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
... UCT Specialties LLC is now,offering their new Product ... in research and development and with input from chemists ... years, each guide is,designed to illustrate and explain the ... it represents., With thousands of calls and monthly ...
... 12 General Research Laboratory,Inc. (GRL) and ... are,advancing their partnership initiated in July 2007 ... products, following the successful,identification of siRNA inhibitors ... of in silico and in vitro studies, ...
... Corporation,(Nasdaq: VOLC ), a leading provider of ... to enhance the diagnosis and,treatment of coronary and ... participating in the Cowen and Company 28th Annual ... presentation by Scott Huennekens, president and chief executive,officer, ...
Cached Biology Technology:UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings 2Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products 2Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products 3Volcano Corporation Presentation at Cowen Healthcare Conference to be Webcast 2
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
(Date:7/7/2015)... 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... mobile commerce market announces a revised version of one of its ... will air on CNBC in New York , ... and San Francisco metro areas.    ... Wocket,s ability to replace all the cards in your wallet and ...
(Date:6/30/2015)... June 30, 2015 Genisphere announced ... CEO to help further develop Genisphere,s therapeutics capabilities and ... experience, having spent much of the last 25 years ... Baxter Bioscience, and Johnson & Johnson. Tom started his ... and Biotech Corporate Finance. He graduated from Dartmouth College ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... A first of its kind combination of experiment ... National Laboratory is providing a close-up look at the ... component of plant cell walls, aggregates to form clumps, ... The exact shape and structure of the aggregates, however, ...
... Palo Alto, CA Although scientists have been able to ... a context for associating the proteins encoded in genes ... underlying plant physiology and ecologyespecially in regard to photosynthesisa ... list of proteins encoded in the genomes of plants ...
... International Osteoporosis Foundation (IOF) in collaboration with the European ... burden of fractures in Europe has been vastly underestimated. ... and Sweden alone, an estimated 2.5 million new ... 280 fractures per hour. It also showed an astounding ...
Cached Biology News:ORNL neutrons, simulations reveal details of bioenergy barrier 2What makes a plant a plant? 2Landmark report reveals immense burden of osteoporotic fractures in Europe 2
... C-terminal reactive. Cross-reacts fully with GLP-1(1-36) ... with the unamidated forms GLP-1(7-37) and ... as hGLP-2, glucagon, hGIP and VIP.,SPECIES ... identical in all mammalian species studied ...
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
... Immunogen: Synthetic peptide derived from the ... rat ZO-1. Specificity: Specific for the ... Reactivity: Human Dog Rat Mouse (positive ... frozen mouse liver heart blood vessel and ...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Biology Products: